First quarter earnings put Pediatrix Medical Group in focus

Pediatrix Medical Group (MD) is back on investors’ radar after its latest first quarter report, which showed higher sales, net income and earnings per share compared with the same period a year earlier.

The earnings update appears to have reset expectations around Pediatrix Medical Group, with a 9.77% 90 day share price return and a 58.79% 1 year total shareholder return indicating stronger momentum compared with the longer term 5 year total shareholder return of negative 25.70%.

If this earnings driven move has you looking beyond Pediatrix, it could be a good time to see which other healthcare related companies are using artificial intelligence in meaningful ways through our 35 healthcare AI stocks.

With a strong 1 year shareholder return, a recent quarterly EPS of US$0.36 and an implied intrinsic discount of around 61%, the key question now is whether Pediatrix is still mispriced or if the market is already accounting for future growth.

Most Popular Narrative: 7.5% Overvalued

The most followed narrative pegs Pediatrix Medical Group’s fair value at $21.33, slightly below the last close of $22.93, framing recent price strength as ahead of that model.

Portfolio restructuring activity has led to a significant 7% decline in consolidated revenue year-over-year, with a $63 million decrease from non-same unit activity, which could indicate volatility in top-line growth and expose the company to further revenue contraction if not offset by robust same-unit gains.

Curious what justifies paying more than this fair value estimate suggests? The narrative leans heavily on steady top line progress, firm margins and a future earnings multiple that assumes investors stay comfortable with that trade off.

Result: Fair Value of $21.33 (OVERVALUED)

However, investors still need to weigh portfolio restructuring related to a 7% revenue decline and rising salary costs, which could pressure margins if revenue growth does not keep up.

Another View: Earnings Multiple Sends A Different Signal

The analyst narrative flags Pediatrix Medical Group as 7.5% overvalued versus a fair value of $21.33, yet the current P/E of 10.6x looks low compared with the US Healthcare industry at 22.4x, the peer average at 24x and an 18.1x fair ratio. This points to a very different risk reward profile.

If the market ever shifted closer to that fair ratio, the re rating would be meaningful. The real question is whether you think the current discount reflects temporary caution or a more permanent reset.

Next Steps

Mixed signals on value and risk so far? Take a moment to review the full picture yourself by weighing both concerns and potential upsides with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Pediatrix has sharpened your focus, do not stop here. Broaden your watchlist with ideas that match different goals and risk levels using the Simply Wall St screener.

• Hunt for mispriced quality by scanning 51 high quality undervalued stocks that pair solid fundamentals with room for the market to reassess them.
• Prioritise staying power by checking solid balance sheet and fundamentals stocks screener (44 results) that can better handle pressure while still offering room for returns.
• Spot tomorrow’s potential standouts early through the screener containing 23 high quality undiscovered gems before they attract wider attention and move out of reach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.